Table 2.
Comparison of operated and non-operated cohorts at hospitals that have included all patients discussed at tumor boards (group 1 hospitals; n=2430)
| Non-operated (n=189) | Operated (n=2241) | Proportion not operated | P value | |
|---|---|---|---|---|
| Age (y) | ||||
| 17–19 | 0 (0) | 6 (0.3) | 0/6 (0) | .793 |
| 20–29 | 6 (3.2) | 53 (2.4) | 6/59 (10.2) | |
| 30–39 | 11 (5.8) | 163 (7.3) | 11/174 (6.3) | |
| 40–49 | 24 (12.7) | 297 (13.3) | 24/321 (7.5) | |
| 50–59 | 38 (20.1) | 555 (24.8) | 38/593 (6.4) | |
| 60–69 | 49 (25.9) | 584 (26.1) | 49/633 (7.7) | |
| 70–79 | 34 (18.0) | 449 (20.0) | 34/483 (7.0) | |
| 80–89 | 26 (13.8) | 130 (5.8) | 26/156 (16.7) | |
| >90 | 1 (0.5) | 4 (0.2) | 1/5 (20) | |
| Income group | ||||
| High | 132 (69.8) | 1885 (84.1) | 132/2017 (6.5) | .003 |
| Upper middle | 21 (11.1) | 236 (10.5) | 21/257 (8.2) | |
| Low-middle | 36 (19.1) | 120 (5.4) | 36/156 (23.1) | |
| BMI (kg/m2) | ||||
| <18.5 | 4 (2.1) | 53 (2.4) | 4/57 (7.0) | .933 |
| 18.5–24.9 | 72 (38.1) | 796 (35.5) | 72/868 (8.3) | |
| 25–29.9 | 43 (22.8) | 636 (28.4) | 43/679 (6.3) | |
| 30–34.9 | 34 (18.0) | 371 (16.6) | 34/405 (8.4) | |
| 35–39.9 | 12 (6.4) | 198 (8.8) | 12/210 (5.7) | |
| ≥40 | 19 (10.1) | 160 (7.1) | 19/179 (10.6) | |
| Not available | 5 (2.7) | 27 (1.2) | 5/32 (15.6) | |
| WHO performance status | ||||
| 0 | 77 (40.7) | 1408 (62.8) | 77/1485 (5.2) | .054 |
| 1 | 79 (41.8) | 601 (26.8) | 79/680 (11.6) | |
| 2 | 25 (13.2) | 153 (6.8) | 25/178 (14.0) | |
| 3 | 4 (2.1) | 24 (1.1) | 4/28 (14.3) | |
| 4 | 2 (1.1) | 2 (0.1) | 2/4 (50) | |
| Not available | 2 (1.1) | 53 (2.4) | 2/4 (50) | |
| CCI | ||||
| 0 | 40 (21.2) | 477 (21.3) | 40/517 (7.7) | .568 |
| 1 | 28 (14.8) | 475 (21.2) | 28/503 (5.6) | |
| 2 | 43 (22.8) | 532 (23.7) | 43/575 (7.5) | |
| 3 | 28 (14.8) | 424 (18.9) | 28/452 (6.2) | |
| 4 | 27 (14.3) | 198 (8.8) | 27/225 (12.0) | |
| 5 | 10 (5.3) | 86 (3.8) | 10/96 (10.4) | |
| 6 | 12 (6.3) | 32 (1.4) | 12/44 (27.3) | |
| 7 | 1 (0.5) | 9 (0.4) | 1/10 (10) | |
| 8 | 0 (0) | 5 (0.2) | 0/5 (0) | |
| 9 | 0 (0) | 3 (0.1) | 0/3 (0) | |
| ASA grade | ||||
| 1 | 36 (19.1) | 536 (23.9) | 36/572 (6.3) | .259 |
| 2 | 91 (48.2) | 1235 (55.1) | 91/1326 (6.9) | |
| 3 | 55 (29.1) | 450 (20.1) | 55/505 (10.9) | |
| 4 | 3 (1.6) | 16 (0.7) | 3/19 (15.8) | |
| 5 | 0 (0) | 1 (<0.1) | 0/1 (0) | |
| Not available | 4 (2.1) | 3 (0.1) | 4/7 (57) | |
| Cancer site | ||||
| Uterus | 60 (31.8) | 1036 (46.2) | 60/1096 (5.5) | .101 |
| Ovary | 104 (55.0) | 798 (35.6) | 104/902 (11.5) | |
| Cervix | 13 (6.9) | 254 (11.3) | 13/267 (4.9) | |
| Vagina/vulva | 12 (6.4) | 152 (6.8) | 12/164 (7.3) | |
| Not available | 0 (0) | 1 (<0.1) | 0/1 (0) | |
| FIGO stagea | ||||
| Not cancer | 9 (4.8) | 121 (5.4) | 9/130 (6.9) | .044 |
| 1 or 2 | 93 (49.2) | 1440 (64.3) | 93/1533 (6.1) | |
| 3 or 4 | 81 (42.9) | 624 (27.8) | 81/705 (11.5) | |
| Not available | 6 (3.2) | 56 (2.5) | 6/62 (9.7) | |
| Lockdown stringency | ||||
| Full | 153 (81.0) | 1186 (52.9) | 153/1339 (11.4) | .001 |
| Moderate | 29 (15.3) | 457 (20.4) | 29/486 (6.0) | |
| Light | 7 (3.7) | 598 (26.7) | 7/605 (1.2) | |
| COVID-19 burden | ||||
| High burden | 136 (72.0) | 1973 (88.0) | 136/2109 (6.5) | .008 |
| Low burden | 53 (28.0) | 321 (13.2) | 53/321 (16.5) |
Data presented as total number (percentage) or proportion (percentage).
ASA grade, American Society of Anaesthesiologists Physical Status Classification system; BMI, body mass index; CCI, Charlson Comorbidity Index; FIGO, International Federation of Gynaecology and Obstetrics; WHO, World Health Organization.
Fotopoulou. Gynecologic cancer surgery during the COVID-19 pandemic. Am J Obstet Gynecol 2022.
a
Comparison of those with cancer and FIGO-stage only.